ThinkstockThe U.S. Food and Drug Administration (FDA) last night rejected an application from Johnson & Johnson (NYSE: JNJ) and Germany’s Bayer A.G. to extend the use of the two companies’ blood thinning…
ThinkstockInvesting in biotech or biopharmaceutical stocks can prove to be a very daunting task. Many of the stocks have limited pipelines or their very survival depends on a single binary event that…
ThinkstockZoetis Inc. (NYSE: ZTS), a spin-off of the animal health business of Pfizer Inc. (NYSE: PFE), held its initial public offering this morning. The company offered 86.1 million shares at $26 a…
Bank of America Merrill Lynch has issued more picks and a macro-investment strategy for 2013, and the message is rather clear: Be selective and position defensively. The firm said that it sees…
These are some of the top analyst upgrades, downgrades and initiations seen in Wall St. research calls this Friday. Active Network Inc. (NYSE: ACTV) raised to Buy at BofA/ML. Allergan Inc. (NYSE: AGN)…
These are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Friday. ADT Corp. (NYSE: ADT) added to the U.S. Focus List at Credit Suisse.…
The three major U.S. stock indexes opened higher this morning following a better-than-expected PMI reading from China (more coverage here) that was mostly untempered by lower-than-expected PMI readings from Europe (more coverage…
Eli Lilly (NYSE: LLY) this morning reported disappointing third-quarter results as generic drugs took a toll on its sales. The Indianapolis-based drug maker posted adjusted earnings per share (EPS) of $0.79 on…
Trey Thoelcke The three major U.S. stock indexes opened lower this morning and remained in negative territory all day. The decline is down to weak earnings from many U.S. firms reporting results today. In…
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Tuesday. Apple Inc. (NASDAQ: AAPL) reiterated Outperform with $750 target at Credit Suisse.…
Eli Lilly & Co. (NYSE: LLY) is confirming prior news showing that late-stage trial data analysis showed the the primary endpoints in cognitive and functional were not met in the two Phase 3,…
Jon C. Ogg Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Wednesday. Activision Blizzard Inc. (NASDAQ: ATVI) started as Buy at Jefferies. Adtran Inc. (NASDAQ:…
The three major U.S. stock indexes opened flat to higher this morning but picked up some buying steam after the first hour or so of trading. In Europe the president of Germany’s…
Jon OggThese are the top analyst calls of upgrades, downgrades and initiations we have seen from Wall St. research calls this Monday morning. Amazon.com Inc. (NASDAQ: AMZN) reiterated Buy with $264 target…
Drugmaker Eli Lilly & Co. (NYSE: LLY) announced this morning that the company’s solanezumab treatment for Alzheimer’s disease failed to meet both the cognitive and functional endpoints in recently completed phase 3…
